Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 3 study to evaluate the efficacy and safety of DKP21102_B Added on to DKP21102_A Compared with DKP21102_A

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dongkwang Pharm. Co., Ltd.

Criteria

Inclusion Criteria:

• A man or woman over 19 years old.

• Patients with coronary heart disease or risk of coronary heart disease

Exclusion Criteria:

• History of Unstable angina, myocardial infarction etc

• Uncontrolled hypo-thyroidism (TSH≥1.5XULN), Diabetes(HbA1c ≥ 9.0%)

• renal impairment (Creatinine clearance < 60 mL/min) etc.